title: Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.
abstract: OBJECTIVE
  To determine the clinical, endocrine, and metabolic effects of acarbose use in overweight and nonoverweight patients with polycystic ovarian syndrome (PCOS).
  
  
  METHODS
  Prospective analysis.
  
  
  METHODS
  Gynecology and infertility clinic of a tertiary care medical center.
  
  
  METHODS
  Seventy-four patients with PCOS and 30 healthy women.
  
  
  METHODS
  Acarbose use.
  
  
  METHODS
  Clinical findings of hyperandrogenism, body mass indices, LH, FSH, DHEAS, total T, PRL, basal insulin, fasting glucose/insulin levels, and lipid profiles.
  
  
  RESULTS
  Acarbose treatment improved LH/FSH levels, decreased total T, DHEAS, basal insulin, low-density lipoprotein, very low-density lipoprotein, and triglyceride levels, and increased high-density lipoprotein levels in patients with PCOS. Basal insulin and fasting glucose/insulin levels reacted more significantly in overweight patients undergoing acarbose treatment.
  
  
  CONCLUSIONS
  Acarbose has been found to improve insulin levels and thus glucose/insulin ratios more effectively in overweight patients compared with nonoverweight patients with PCOS. This drug seems to be an effective drug to be used in overweight as well as nonoverweight patients with PCOS.
authors: Zeynep Kamil Women's and Children's Hospital, Istanbul, Turkey.
authors: Semih
authors: S
authors: Tuğrul
authors: Tayfun
authors: T
authors: Kutlu
authors: Oya
authors: O
authors: Pekin
authors: Elif
authors: E
authors: Bağlam
authors: Hüseyin
authors: H
authors: Kiyak
authors: Ozay
authors: O
authors: Oral
mesh_terms: D020909:Acarbose / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood*; D009765:Obesity / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D020909:Acarbose